T. Scott Stroup, MD

Brief Video Intervention to Reduce Self-Stigma of Mental Illness

March 6, 2024

A 2-minute social contact–based video intervention decreased self-stigma in young people with ongoing mental health conditions.

Doron Amsalem , Samantha E. Jankowski , Philip Yanos , et al

Original Research

Heterogeneity of Treatment Effects of LAI Antipsychotics

November 27, 2018

Which subgroups of patients with schizophrenia or schizoaffective disorder may be prone to treatment failure? Is it men or women, old or young, or are more factors involved? Researchers...

T. Scott Stroup , Natalie A. Bareis , Robert A. Rosenheck , et al

Original Research

Antipsychotic Medications in Adult Depression

July 5, 2017

Antipsychotic medications are increasingly prescribed to treat depression. But is this use always warranted? Read the article by Gerhard and colleagues to learn how often antipsychotics are prescribed in...

Tobias Gerhard , T. Scott Stroup , Christoph U. Correll , et al

Commentary

What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?

November 24, 2014

T. Scott Stroup

Original Research

Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial

May 15, 2012

Richard S. E. Keefe , Sophia Vinogradov , Alice Medalia , et al

Article

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

April 15, 2012

Eric D. A. Hermes , Daniel Sokoloff , T. Scott Stroup , et al

Original Research

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

March 6, 2012

Nancy H. Covell , Joseph P. McEvoy , Nina R. Schooler , et al

Original Research

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

August 10, 2010

Stanley N. Caroff , Vicki G. Davis , Del D. Miller , et al

Original Research

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

November 15, 2007

Troy A. Moore , Robert W. Buchanan , Peter F. Buckley , et al

Brief Video Intervention to Reduce Self-Stigma of Mental Illness

Heterogeneity of Treatment Effects of LAI Antipsychotics

Antipsychotic Medications in Adult Depression

What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?

Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

ELSEWHERE:

FOLLOW US:

T. Scott Stroup, MD

Brief Video Intervention to Reduce Self-Stigma of Mental Illness

Heterogeneity of Treatment Effects of LAI Antipsychotics

Antipsychotic Medications in Adult Depression

What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?

Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update

Watch the New PsychCase360